As for IL-17, it was shown a significant decrease in AML patients (median, 1.1×10−4, range 1.2×10−5-3.9×10−3) compared with in controls (median, 6.6×10−4, range 5.2×10−5-5.1×10−3; P = 0.00) (Figure 4F). Here, IL17A is linked to acute myeloid leukemia.